ArticlePloS one2026
System immunoinformatics-based design of a multi-epitope vaccine candidate against La Crosse virus.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A novel multi-epitope mRNA vaccine against Escherichia coli using an in silico reverse vaccinology approach.Journal of applied genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of La Crosse virus (LACV) infection has been attributed to the global expansion of mosquito habitats and climate change. This pressing issue underscores the urgency of preemptive actions to combat the infection. Currently, no vaccines or targeted antivirals are available for LACV infection. The present study utilizes advanced immunoinformatics approaches for the design of a multiepitope vaccine (LACV-mVax01) targeting the viral proteins G1, G2, and N. The structural assessment suggested favorable stability characteristics, reflected by an instability score of 17.12 and an aliphatic index of 81.88. Based on the two-dimensional structure, the LACV-mVax01 had an alpha-helical content of ~45%, with favorable beta sheets and coils. The refinement of the LACV-mVax01 resulted in an accurate model (TM-score 0.49, C-score -1.86), supported by high-quality metrics (RMSD 0.489, MolProbity 2.230, ERRAT 85.539). Docking analyses indicated potential binding interactions with TLR4, showing a binding energy of -1000.0 compared to -939.2 for TLR2. Molecular dynamics simulations were consistent with these observations, suggesting relatively stable interactions and maintenance of structural integrity in both complexes. Codon optimization yielded a codon adaptation index of 0.9848, and the predicted mRNA structure had a free energy of -342.16 kcal/mol, consistent with a stable conformation. Subsequent in silico immunological analyses suggested humoral and cellular responses, including probable memory B- and T-cell responses. However, sustained immunity was also supported by consecutive cytokine and antibody synthesis. The comprehensive structural, molecular, and immunological evaluations suggest that LACV-mVax01 is a promising vaccine candidate capable of eliciting sustained protective immunity against LACV infection. Though future in vitro, in vivo, and clinical validations are required to perceive its effectiveness and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.